DOCSLIB.ORG
  • Sign Up
  • Log In
  • Upload
  • Sign Up
  • Log In
  • Upload
  • Home
  • »  Tags
  • »  Carbidopa

Carbidopa

  • (12) Patent Application Publication (10) Pub. No.: US 2013/0253056A1 Nemas Et Al

    (12) Patent Application Publication (10) Pub. No.: US 2013/0253056A1 Nemas Et Al

  • PSP: Some Answers

    PSP: Some Answers

  • Carbidopa and Levodopa | Memorial Sloan Kettering Cancer Center

    Carbidopa and Levodopa | Memorial Sloan Kettering Cancer Center

  • Azilect, INN-Rasagiline

    Azilect, INN-Rasagiline

  • Parkinson's Disease Fact Sheet

    Parkinson's Disease Fact Sheet

  • Download

    Download

  • New Drugs Approved in FY 2014

    New Drugs Approved in FY 2014

  • S41467-019-09610-2.Pdf

    S41467-019-09610-2.Pdf

  • Parkinson's and Diet

    Parkinson's and Diet

  • ZELAPAR™ (Selegiline Hydrochloride) Orally Disintegrating Tablets

    ZELAPAR™ (Selegiline Hydrochloride) Orally Disintegrating Tablets

  • World Health Organization Model List of Essential Medicines, 21St List, 2019

    World Health Organization Model List of Essential Medicines, 21St List, 2019

  • Third Quarter 2017 Update

    Third Quarter 2017 Update

  • Induced Catecholamine Depletion in Patients with Seasonal Affective Disorder in Summer Remission Raymond W

    Induced Catecholamine Depletion in Patients with Seasonal Affective Disorder in Summer Remission Raymond W

  • Drugs Associated with an Increased Falls Risk

    Drugs Associated with an Increased Falls Risk

  • Initial Experience of the Levodopa–Entacapone–Carbidopa Intestinal Gel in Clinical Practice

    Initial Experience of the Levodopa–Entacapone–Carbidopa Intestinal Gel in Clinical Practice

  • Rasagiline NDC 0378- -93 Dispense in a Tight, Light-Resistant Mesylate Equivalent to 0.5 Mg 1270 Container As Defined in the USP of Rasagiline

    Rasagiline NDC 0378- -93 Dispense in a Tight, Light-Resistant Mesylate Equivalent to 0.5 Mg 1270 Container As Defined in the USP of Rasagiline

  • Jack Deruiter, Principles of Drug Action 2, Fall 2001

    Jack Deruiter, Principles of Drug Action 2, Fall 2001

  • Randomized, Placebo-Controlled Study of Tolcapone in Patients with Fluctuating Parkinson Disease Treated with Levodopa-Carbidopa

    Randomized, Placebo-Controlled Study of Tolcapone in Patients with Fluctuating Parkinson Disease Treated with Levodopa-Carbidopa

Top View
  • Carbidopa-Levodopa-Entacapone (Stalevo)
  • Launch of Ongentys® Tablets 25Mg, a Peripheral COMT Inhibitor in Japan
  • Parkinson's Treatment “Tips & Pearls”
  • Parkinson's Disease
  • High-Risk Medications in the Elderly
  • PSP: Some Answers
  • Ongentys) Reference Number: CP.PMN.245 Effective Date: 09.01.20 Last Review Date: 08.20 Line of Business: Commercial, HIM, Medicaid Revision Log
  • TASMAR* (Tolcapone) RATIONALE for INCLUSION in PA PROGRAM
  • Attachment: Product Information for Opicapone
  • Safinamide (Xadago) Reference Number: ERX.NPA.45 Effective Date: 09.01.17 Last Review Date: 02.21 Line of Business: Commercial, Medicaid Revision Log
  • Highlighted the Attributes of Dupixent. Syed Mahmod from PYC Therapeutic: Highlighted the Attributes of Emflaza
  • Mammalian Dopa Decarboxylase: Structure, Catalytic Activity and Inhibition Q ⇑ Mariarita Bertoldi
  • TASMAR® (Tolcapone) TABLETS
  • Parkinson's Disease Medications
  • Medications Approved for the Treatment of Parkinson's Disease In
  • Levodopa/Carbidopa/Entacapone Orion, INN-Levodopa, Carbidopa
  • Practical Guidelines for Management of Parkinson Disease
  • Tasmar (Tolcapone) Is a Selective and Reversible Inhibitor of Catechol-O-Methyltransferase (COMT)


© 2024 Docslib.org    Feedback